Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03168412
Recruitment Status : Completed
First Posted : May 30, 2017
Last Update Posted : February 21, 2019
Sponsor:
Information provided by (Responsible Party):
Xiamen Innovax Biotech Co., Ltd

Brief Summary:
This phase IV clinical study was designed to evaluate the immunogenicity and safety of the recombinant Hepatitis E vaccine (Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults (over 18 years) with accelerated vaccination schedule. The study volunteers will receive the 3 doses of Hecolin® administered intramuscularly according to a 0-7-21 days schedule or a 0-1-6 month schedule.

Condition or disease Intervention/treatment Phase
Hepatitis E Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 125 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years)
Actual Study Start Date : May 25, 2017
Actual Primary Completion Date : July 15, 2018
Actual Study Completion Date : November 28, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: the Accelerated Vaccination Schedule Group
Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
Other Name: Hecolin®

Active Comparator: the Standard Vaccination Schedule Group
Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Other Name: Hecolin®




Primary Outcome Measures :
  1. Anti-HEV antibody of Experimental Group [ Time Frame: up to 2 months ]
    Measure anti-HEV antibody in serum samples at 51st day to evaluate the immunogenicity of the Hepatitis E vaccine.


Secondary Outcome Measures :
  1. Adverse reactions/events of Experimental Group and Control Group [ Time Frame: up to 7 months ]
    Measure solicited local adverse reactions/events within 7 days after each vaccination; Measure solicited systematic adverse reactions/events within 7 days after each vaccination; Measure unsolicited adverse reactions/events within 30 days after vaccination; Measure serious adverse events occurred throughout the study(up to 7 months).

  2. Anti-HEV antibody of Experimental Group [ Time Frame: up to 7 months ]
    Measure anti-HEV antibody in serum samples at 21st day,28st day and month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.

  3. Anti-HEV antibody of Control Group [ Time Frame: up to 7 months ]
    Measure anti-HEV antibody in serum samples at month 1,2,7 to evaluate the immunogenicity of the Hepatitis E vaccine.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Aged over 18 years old on the day of enrollment, including 18 years old;
  2. Axillary temperature is below than 37.0 ℃;
  3. Negative serological markers for hepatitis E and liver function are normal or no clinical significance;
  4. Judged as healthy and eligible for vaccination by the investigators through a selfreported medical history and some physical examinations;
  5. Able to understand this study information and willing to comply with all study requirements;
  6. Willing to participate in this study and sign informed consent form.

Exclusion Criteria:

  1. Pregnancy,breast-feeding or plan to be pregnant in 7 months;
  2. Administration of Hepatitis E Vaccine before the study;
  3. Participate in any other clinical trial during the study period;
  4. Use of any investigational product or non-registered product (drug or vaccine)within 30 days preceding the first dose of the study vaccine or plan to use during the study period;
  5. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment;
  6. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period;
  7. Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study;
  8. Had a fever (axillary temperature over 38°C) within 3 days or acute illness, or use systemic antibiotics or antiviral treatment within 5 days before vaccination;
  9. Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response), liver and kidney disease and other chronic disease history;
  10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain. Allergic history to any component of this vaccine.
  11. Asthma that needed emergency treatment, hospitalization, oral or intravenous corticosteroid to keep stable in the past two years;
  12. Combining another severe internal medicine disease(such as cardiopathy,diabetes and hyperthyroidism)
  13. Anormal coagulation function or coagulopathy diagnosed by doctor;
  14. Epilepsy(not including alcohol epilepsy within 3 years prior to abstinence and simple epilepsy that do without curing within 3 years prior to the study )
  15. Anomal psychology or mind affecting the individual's ability to obey the study requirement;
  16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment,might affect the individual's ability to obey the protocol or sign the informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03168412


Locations
Layout table for location information
China, Zhejiang
Changshan Center for Disease Control and Prevention
Quzhou, Zhejiang, China, 324200
Sponsors and Collaborators
Xiamen Innovax Biotech Co., Ltd
Investigators
Layout table for investigator information
Principal Investigator: Zhiping Chen Zhejiang Provincial Center for Disease Control and Prevention
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Xiamen Innovax Biotech Co., Ltd
ClinicalTrials.gov Identifier: NCT03168412    
Other Study ID Numbers: PRO-HE-008
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: February 21, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xiamen Innovax Biotech Co., Ltd:
Hepatitis E
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis E
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs